OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally.
The last earnings update was 49 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
OpGen. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
OpGen's earnings available for a low price, and how does
this compare to other companies in the same industry?
OpGen is not considered high growth as it is expected to be loss making for the next 1-3 years.
OpGen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
OpGen's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Evan Jones, M.B.A., serves as Executive Chairman of jVEN Capital, LLC. Mr. Jones founded and has served as Managing Member of jVEN Capital, LLC since July 2007. Mr. Jones has been Chief Executive Officer and Chairman of the Board at OpGen, Inc. since October 2013 and served as its President from October 2013 to April 2015. He served as an Interim Chief Executive Officer at OpGen, Inc. from December 2009 to June 2010 and served as its Chairman since September 1995 and Director since July 1990. He served as the Chief Executive Officer from July 1990 to November 22, 2006 and President from July 1990 to June 1999 at QIAGEN Gaithersburg Inc., which he founded in July 1990. Mr. Jones was a Co-Founder of Digene Corporation and was its Chairman from 1995 to 2007, Chief Executive Officer from 1990 to 2006 and President from 1990 to 1999. From 1988 to September 1990, he served as the President at Neomorphics, Inc. From 1987 to 1990, He served as an Associate at CW Group, Inc. He has also worked at Applied Biosystems, Inc. From 1983 to 1987, he was employed at Perkin-Elmer Corporation. He also serves on the Board of Directors of Research!America. Mr. Jones served as a member of the board of directors of CAS Medical Systems, Inc. (NASDAQ: CASM), a developer of patient vital signs monitoring products and technologies, from June 2008 to October 2013. He serves as the Chairman of the Campaign for Public Health and served as the Chairman of the Board of Children's Research Institute at the Children's National Medical Center. He serves as Vice Chairman of Children's National Health System. He served as an Independent Director at Foundation Medicine, Inc. from January 2013 to July 31, 2018. He has been a Director of Veracyte, Inc. since February 2008. He is a Director at OpGen since 2009. He serves as a Member of the Board of Directors of the Children’s Research Institute where he was Chairman and Children’s National Medical Center and the Board of Visitors of the University Of Maryland College Of Life Sciences. He served as a Director of Fluidigm Corporation from April 4, 2011 to August 1, 2017. He served as the Chairman of Signature Genomic Laboratories, LLC from June 2008 to May 2010. He has more than 30 years of operating and investment experience in the life sciences industry, where he founded or helped start numerous life sciences companies. He received an M.B.A. from Wharton School at University of Pennsylvania and a B.A. in Biochemistry/Biotechnology from the University of Colorado.
Evan's compensation has been consistent with company performance over the past year.
Evan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the OpGen management team is over 5 years, this suggests they are a seasoned and experienced team.
Chairman & CEO
CFO & Corporate Secretary
Chief Information Officer
Vice President of Marketing
Senior Vice President of Research & Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the OpGen board of directors is about average.
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company’s products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.